In a letter to the Guardian in response to the news that the U.K. Department for International Development (DfID) plans to cut bilateral aid for HIV/AIDS by nearly one-third, Nathan Ford, medical coordinator for Medecins Sans Frontieres, writes that the agency’s decision “comes at a critical moment,” after “[v]arious studies published in the past year have shown widespread access to treatment and prevention can dramatically cut HIV/AIDS transmission, and allow for consideration of an end to the epidemic.”
The Huffington Post profiles Philippe Douste-Blazy, U.N. under-secretary-general of Innovative Financing for Development and chair of UNITAID, a financing mechanism he conceived in 2004 to help provide medicines for HIV, tuberculosis and malaria in developing countries. The article discusses Douste-Blazy’s work and background, UNITAID, and other innovative financing schemes (Lines, 10/6).
Fred Sawe, deputy director of the Kenya Medical Research Institute/Walter Reed Project HIV Program in Kericho, Kenya, and Mitchell Warren, executive director of AVAC: Global Advocacy for HIV Prevention, report in Global Health Magazine that “[t]he Department of the Army is set to slash 73 percent of the U.S. Military HIV…
Experts Take Study On Contraceptive Use, HIV Risk Seriously But Warn About Drawing Conclusions Prematurely Because Of Study's 'Methodological Weaknesses'
In this post in RH Reality Check, Jodi Jacobson, editor-in-chief of the blog, responds to an article published in the New York Times on Tuesday regarding a study suggesting that “HIV-negative women using injectable contraception might face a two-fold risk of acquiring HIV from their infected partners, and that HIV-positive women using…
Investments to keep 3.5 million people living with HIV on antiretroviral drugs provided by programs co-financed through the Global Fund to Fight AIDS, Tuberculosis and Malaria through 2020 will cost an estimated $14.2 billion, but “the financial savings would amount to between $12 billion and $34 billion,” according to a study published in the journal PLoS One, Sarah Boseley reports in her “Global Health Blog” in the Guardian (10/5).
The Huffington Post, as part of a collaboration on trade issues with the Dylan Ratigan Show, examines how “a new trade deal the Obama administration is pushing to complete with Vietnam and seven other Pacific nations threatens to seriously hinder both U.S. and international efforts to combat AIDS — including the government’s own efforts in Vietnam.” Under the Trans-Pacific Partnership, “U.S. negotiators are seeking to impose a set of restrictive intellectual property laws that would help American drug companies secure long-term monopolies overseas,” according to leaked documents, the Huffington Post writes.
“For every 1,000 patient-years of PEPFAR-supported HIV treatment provided, 228 fewer HIV patients die, 449 fewer children become orphans, 61 fewer sexual HIV transmissions occur and 26 fewer ‘vertical’ transmissions (e.g. mother-to-child) occur,” John Blanford of the CDC told the PEPFAR Scientific Advisory Board in Washington, D.C., on September 14,…
Britain is cutting bilateral aid for HIV/AIDS projects in developing countries by 32 percent, from 59.9 million pounds to 41 million pounds, between now and 2015, according to data from the Department for International Development (DfID), the Guardian reports. “The drop in support comes despite a 92 percent rise in Britain’s bilateral aid for global health, from 376 million pounds to 723 million pounds by 2015, when reproductive, maternal and newborn health will absorb 64 percent of DfID’s global health funding,” the newspaper writes.
A UNAIDS feature story reports on a roundtable discussion held at the Centre for the AIDS Programme of Research (CAPRISA) in South Africa last month, which “looked at ways of maximizing the opportunities created by scientific research around HIV prevention in the past year to reach the country’s target of halving…
A new quick test to determine the CD4 levels of individuals who test positive for HIV “resulted in a substantial increase” in the percentage of people returning to a clinic get those results, according to a study conducted in Mozambique and published last week in the Lancet, the New York Times reports. “Before quick testing was available, 42 percent of infected patients returned to learn their CD4 count at a subsequent visit. After point-of-care testing began, 78 percent of infected patients were evaluated — that is, almost twice as many infected people took this important first step toward drug treatment,” the newspaper writes (Bakalar, 10/3).